NovoCure (NVCR) Common Equity (2014 - 2026)

NovoCure has disclosed Common Equity across 13 years of filings, most recently posting $330.7 million for Q1 2026.

• Common Equity for Q1 2026 came in at $330.7 million, down 8.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $330.7 million (down 8.63% YoY), and the FY2025 annual result was $340.5 million, down 5.47% from the prior year.
• Common Equity came in at $330.7 million for Q1 2026 at NovoCure, down from $340.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $445.4 million in Q3 2022 to a low of $330.7 million in Q1 2026.
• The 5-year median for Common Equity is $362.0 million (2025), against an average of $384.4 million.
• Across the five-year window, Common Equity increased 17.13% in 2022 and declined 17.83% in 2023, its largest moves.
• NovoCure's Common Equity stood at $441.2 million in 2022, then decreased by 17.83% to $362.5 million in 2023, then retreated by 0.64% to $360.2 million in 2024, then slipped by 5.47% to $340.5 million in 2025, then declined by 2.86% to $330.7 million in 2026.
• The last three Common Equity figures came in at $330.7 million (Q1 2026), $340.5 million (Q4 2025), and $341.3 million (Q3 2025), per Business Quant data.